Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Chemotherapy for Lung Cancer in the Era of Personalized Medicine

  • Lee, Seung Hyeun (Division of Respiratory, Allergy and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University School of Medicine)
  • Received : 2018.08.17
  • Accepted : 2018.09.26
  • Published : 2019.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Although recent advances in molecular targeted therapy and immuno-oncology have revolutionized the landscape of lung cancer therapeutics, cytotoxic chemotherapy remains an essential component of lung cancer treatment. Extensive evidence has demonstrated the clinical benefit of chemotherapy, either alone or in combination with other treatment modalities, on survival and quality of life of patients with early and advanced lung cancer. Combinational approaches with other classes of anti-neoplastic agents and new drug-delivery systems have revealed promising data and are areas of active investigation. Chemotherapy is recommended as a standard of care in patients that have progressed after tyrosine kinase inhibitors or immune checkpoint inhibitors. Chemotherapy remains the fundamental means of lung cancer management and keeps expanding its clinical implication. This review will discuss the current position and future role of chemotherapy, and specific consideration for its clinical application in the era of precision medicine.

Keywords

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. https://doi.org/10.3322/caac.21262
  2. Park JY, Jang SH. Epidemiology of lung cancer in Korea: recent trends. Tuberc Respir Dis 2016;79:58-69. https://doi.org/10.4046/trd.2016.79.2.58
  3. Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent advances in targetable therapeutics in metastatic non-squamous NSCLC. Front Oncol 2016;6:112.
  4. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-33. https://doi.org/10.1056/NEJMoa1606774
  5. Peters S, Gettinger S, Johnson ML, Janne PA, Garassino MC, Christoph D, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed deathligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol 2017;35:2781-9. https://doi.org/10.1200/JCO.2016.71.9476
  6. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39. https://doi.org/10.1056/NEJMoa1507643
  7. Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res 2015;4:156-64. https://doi.org/10.3978/j.issn.2218-6751.2014.11.11
  8. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v1-27. https://doi.org/10.1093/annonc/mdw326
  9. Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2017;35:3484-515. https://doi.org/10.1200/JCO.2017.74.6065
  10. National Comprehensive Cancer Network guidelines [Internet]. Plymouth Meeting: National Comprehensive Cancer Network; 2018 [cited 2018 Aug 15]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
  11. Karnofsky DA. Chemotherapy of neoplastic disease: agents of clinical value. N Engl J Med 1948;239:299-305. https://doi.org/10.1056/NEJM194808192390805
  12. Rockswold GL, Ramsey HE, Buker GD. The results of treatment of lung cancer by surgery, radiation and chemotherapy at a USPHS hospital. Mil Med 1970;135:362-8. https://doi.org/10.1093/milmed/135.5.362
  13. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909. https://doi.org/10.1136/bmj.311.7010.899
  14. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005;23:2926-36. https://doi.org/10.1200/JCO.2005.03.045
  15. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. https://doi.org/10.1056/NEJMoa011954
  16. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51. https://doi.org/10.1200/JCO.2007.15.0375
  17. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-smallcell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-40. https://doi.org/10.1016/S0140-6736(09)61497-5
  18. Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol 2013;14:777-86. https://doi.org/10.1016/S1470-2045(13)70254-7
  19. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078-92. https://doi.org/10.1056/NEJMoa1801005
  20. Santabarbara G, Maione P, Rossi A, Gridelli C. Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy. Expert Opin Pharmacother 2016;17:561-70. https://doi.org/10.1517/14656566.2016.1122757
  21. Rossi A, Di Maio M. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Expert Rev Anticancer Ther 2016;16:653-60. https://doi.org/10.1586/14737140.2016.1170596
  22. Lima JP, dos Santos LV, Sasse EC, Sasse AD. Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis. Eur J Cancer 2009;45:601-7. https://doi.org/10.1016/j.ejca.2008.11.006
  23. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009;27:3277-83. https://doi.org/10.1200/JCO.2008.19.4522
  24. Rossi A, Chiodini P, Sun JM, O'Brien ME, von Plessen C, Barata F, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2014;15:1254-62. https://doi.org/10.1016/S1470-2045(14)70402-4
  25. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13:247-55. https://doi.org/10.1016/S1470-2045(12)70063-3
  26. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895-902. https://doi.org/10.1200/JCO.2012.47.1102
  27. Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol 2012;13:292-9. https://doi.org/10.1016/S1470-2045(11)70339-4
  28. Paik SS, Hwang IK, Park MJ, Lee SH. Pemetrexed continuation maintenance versus conventional platinum-based doublet chemotherapy in EGFR-negative lung adenocarcinoma: retrospective analysis. Tuberc Respir Dis 2018;81:148-55. https://doi.org/10.4046/trd.2017.0090
  29. Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther 2018;3:7. https://doi.org/10.1038/s41392-017-0004-3
  30. Blair HA, Deeks ED. Albumin-bound paclitaxel: a review in non-small cell lung cancer. Drugs 2015;75:2017-24. https://doi.org/10.1007/s40265-015-0484-9
  31. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012;30:2055-62. https://doi.org/10.1200/JCO.2011.39.5848
  32. Socinski MA, Langer CJ, Okamoto I, Hon JK, Hirsh V, Dakhil SR, et al. Safety and efficacy of weekly nab(R)-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24:314-21. https://doi.org/10.1093/annonc/mds461
  33. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013;12:329-32. https://doi.org/10.1038/nrd4009
  34. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91. https://doi.org/10.1056/NEJMoa1209124
  35. Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol 2018;36:2532-7. https://doi.org/10.1200/JCO.2018.77.9777
  36. Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 2015;7:302ra136. https://doi.org/10.1126/scitranslmed.aac9459
  37. Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 2017;18:42-51. https://doi.org/10.1016/S1470-2045(16)30565-4
  38. ClinicalTrials.gov [Internet]. Bethesda: U.S. National Library of Medicine; 2018 [cited 2018 Aug 15]. Available from: https://clinicaltrials.gov.
  39. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. https://doi.org/10.1056/NEJMoa061884
  40. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34. https://doi.org/10.1200/JCO.2007.14.5466
  41. Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol 2015;33:2197-204. https://doi.org/10.1200/JCO.2014.59.4424
  42. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-9. https://doi.org/10.1093/annonc/mdq020
  43. Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinumbased chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24:20-30. https://doi.org/10.1093/annonc/mds590
  44. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2017;18:1610-23. https://doi.org/10.1016/S1470-2045(17)30691-5
  45. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV nonsmall-cell lung cancer after disease progression on platinumbased therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384:665-73. https://doi.org/10.1016/S0140-6736(14)60845-X
  46. Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): a randomized, double-blind, phase III trial. Lung Cancer 2016;102:65-73. https://doi.org/10.1016/j.lungcan.2016.10.011
  47. Fenchel K, Sellmann L, Dempke WC. Overall survival in nonsmall cell lung cancer-what is clinically meaningful? Transl Lung Cancer Res 2016;5:115-9.
  48. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006. https://doi.org/10.1001/jama.2014.3741
  49. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 2004;22:777-84. https://doi.org/10.1200/jco.2004.22.14_suppl.777
  50. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-52. https://doi.org/10.1200/JCO.2005.05.1474
  51. Zheng Y, Xu N, Zhou J. Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? Lancet Oncol 2013;14:e438. https://doi.org/10.1016/S1470-2045(13)70412-1
  52. Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, et al. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology 2013;2:e27025. https://doi.org/10.4161/onci.27025
  53. Jackaman C, Majewski D, Fox SA, Nowak AK, Nelson DJ. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo. Cancer Immunol Immunother 2012;61:2343-56. https://doi.org/10.1007/s00262-012-1307-4
  54. Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010;102:115-23. https://doi.org/10.1038/sj.bjc.6605465
  55. Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology 2017;6:e1331807. https://doi.org/10.1080/2162402X.2017.1331807
  56. Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 2015;3:436-43. https://doi.org/10.1158/2326-6066.CIR-15-0064
  57. Ramakrishnan R, Gabrilovich DI. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother 2013;62:405-10. https://doi.org/10.1007/s00262-012-1390-6
  58. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:1497-508. https://doi.org/10.1016/S1470-2045(16)30498-3
  59. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60. https://doi.org/10.1056/NEJMoa031644
  60. Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatinbased chemotherapy in resected lung cancer. J Clin Oncol 2010;28:35-42. https://doi.org/10.1200/JCO.2009.23.2272
  61. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27. https://doi.org/10.1016/S1470-2045(06)70804-X
  62. Douillard JY, Tribodet H, Aubert D, Shepherd FA, Rosell R, Ding K, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol 2010;5:220-8. https://doi.org/10.1097/JTO.0b013e3181c814e7
  63. Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, et al. Adjuvant chemotherapy for resected earlystage non-small cell lung cancer. Cochrane Database Syst Rev 2015;(3):CD011430.
  64. Park SY, Lee JG, Kim J, Byun GE, Bae MK, Lee CY, et al. Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer. J Cardiothorac Surg 2013;8:151. https://doi.org/10.1186/1749-8090-8-151
  65. Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. J Clin Oncol 2015;33:870-6. https://doi.org/10.1200/JCO.2014.58.5380
  66. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-30. https://doi.org/10.1056/NEJM199202203260805
  67. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III nonsmall-cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-70. https://doi.org/10.1200/JCO.1996.14.4.1065
  68. Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103:1452-60. https://doi.org/10.1093/jnci/djr325
  69. Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2016;34:953-62. https://doi.org/10.1200/JCO.2015.64.8824
  70. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561-5. https://doi.org/10.1056/NEJM199008303230902
  71. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5240-7. https://doi.org/10.1200/JCO.2007.12.6953
  72. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008;26:1472-8. https://doi.org/10.1200/JCO.2007.13.0062
  73. Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 2013;31:1112-21. https://doi.org/10.1200/JCO.2012.43.0454
  74. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004;14:959-70.
  75. Rosell R, Lord RV, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002;38:217-27. https://doi.org/10.1016/S0169-5002(02)00224-6
  76. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
  77. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91. https://doi.org/10.1056/NEJMoa060570
  78. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-83. https://doi.org/10.1378/chest.127.3.978
  79. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25:2747-54. https://doi.org/10.1200/JCO.2006.09.7915
  80. Lee SM, Falzon M, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, et al. Randomized prospective biomarker trial of ERCC1 for comparing platinum and nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). J Clin Oncol 2017;35:402-11.
  81. Toffart AC, Timsit JF, Couraud S, Merle P, Moro-Sibilot D, Perol M, et al. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). Lung Cancer 2014;83:182-8. https://doi.org/10.1016/j.lungcan.2013.12.003
  82. Bonanno L. Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2013;2:160-71. https://doi.org/10.3978/j.issn.2218-6751.2013.03.07
  83. Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998;82:1626-31. https://doi.org/10.1002/(SICI)1097-0142(19980501)82:9<1626::AID-CNCR5>3.0.CO;2-8
  84. Harpole DH Jr, Moore MB, Herndon JE 2nd, Aloia T, D'Amico TA, Sporn T, et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2001;7:562-9.
  85. Edler D, Kressner U, Ragnhammar P, Johnston PG, Magnusson I, Glimelius B, et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 2000;6:488-92.
  86. Huang C, Liu D, Masuya D, Nakashima T, Kameyama K, Ishikawa S, et al. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 2005;92:1231-9. https://doi.org/10.1038/sj.bjc.6602481
  87. Shimokawa H, Uramoto H, Onitsuka T, Iwata T, Nakagawa M, Ono K, et al. TS expression predicts postoperative recurrence in adenocarcinoma of the lung. Lung Cancer 2011;72:360-4. https://doi.org/10.1016/j.lungcan.2010.08.024
  88. Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable nonsmall cell lung cancer. J Thorac Oncol 2008;3:1112-8. https://doi.org/10.1097/JTO.0b013e3181874936
  89. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-96. https://doi.org/10.1002/cncr.22208
  90. Monica V, Scagliotti GV, Ceppi P, Righi L, Cambieri A, Lo Iacono M, et al. Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res 2009;15:7547-52. https://doi.org/10.1158/1078-0432.CCR-09-1641
  91. Hashimoto H, Ozeki Y, Sato M, Obara K, Matsutani N, Nakagishi Y, et al. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 2006;106:1595-601. https://doi.org/10.1002/cncr.21777
  92. Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, et al. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol 2013;8:19-30. https://doi.org/10.1097/JTO.0b013e31827628ff
  93. Lee SH, Noh KB, Lee JS, Lee EJ, Min KH, Hur GY, et al. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer 2013;81:102-8. https://doi.org/10.1016/j.lungcan.2013.03.002
  94. Sun JM, Ahn JS, Jung SH, Sun J, Ha SY, Han J, et al. Pemetrexed plus cisplatin versus gemcitabine plus cisplatin according to thymidylate synthase expression in nonsquamous nonsmall-cell lung cancer: a biomarker-stratified randomized phase II trial. J Clin Oncol 2015;33:2450-6. https://doi.org/10.1200/JCO.2014.59.9324
  95. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94. https://doi.org/10.1056/NEJMoa1214886
  96. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALKpositive lung cancer. N Engl J Med 2014;371:2167-77. https://doi.org/10.1056/NEJMoa1408440
  97. Drilon A, Bergagnini I, Delasos L, Sabari J, Woo KM, Plodkowski A, et al. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Ann Oncol 2016;27:1286-91. https://doi.org/10.1093/annonc/mdw163
  98. Chen YF, Hsieh MS, Wu SG, Chang YL, Yu CJ, Yang JC, et al. Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations. J Thorac Oncol 2016;11:1140-52. https://doi.org/10.1016/j.jtho.2016.03.022

Cited by

  1. Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway vol.38, pp.1, 2019, https://doi.org/10.1186/s13046-019-1353-2
  2. Current Status of Immunotherapy for Lung Cancer and Future Perspectives vol.83, pp.1, 2020, https://doi.org/10.4046/trd.2019.0039
  3. Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer vol.13, pp.1, 2019, https://doi.org/10.1016/j.path.2019.11.002
  4. Serum Reactive Oxygen Species Modulator 1 as a Novel Predictive Biomarker for Resected Lung Adenocarcinoma: A Retrospective Pilot Study vol.14, 2021, https://doi.org/10.2147/ott.s336399
  5. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer vol.2021, 2019, https://doi.org/10.1155/2021/1951364
  6. Mechanisms of resistance to chemotherapy in non-small cell lung cancer vol.44, pp.2, 2019, https://doi.org/10.1007/s12272-021-01312-y
  7. 2D Nanomaterial, Ti3C2 MXene-Based Sensor to Guide Lung Cancer Therapy and Management vol.11, pp.2, 2019, https://doi.org/10.3390/bios11020040
  8. Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum‐based doublet chemotherapy and immunotherapy ( SPACE study) vol.12, pp.8, 2019, https://doi.org/10.1111/1759-7714.13880
  9. Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products vol.26, pp.13, 2021, https://doi.org/10.3390/molecules26134100
  10. Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non–small cell lung cancer vol.162, pp.2, 2019, https://doi.org/10.1016/j.jtcvs.2020.03.166
  11. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours vol.125, pp.4, 2019, https://doi.org/10.1038/s41416-021-01405-x